This pathway is conserved between various cell types, and data from patient samples and pre-clinical mouse models indicate that GRAF1 dysregulation contributes to (and may be a viable therapeutic target for) heart failure and perhaps other cardiometabolic or neurological diseases that result from failed mitochondrial clearance. Here, ARHGAP26 is linked to heart failure.